Gilead’s (GILD) Yeztugo, or lenacapavir, a human immunodeficiency virus type 1 capsid inhibitor, is indicated for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition, according to prescribing information posted to the site of the FDA. Lenacapavir for the prevention of HIV has a June 19 PDUFA deadline date.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead receives FDA approval for HIV prevention injection
- Gilead Sciences: Strong HIV Market Position and Diversified Growth Strategy Justify Buy Rating
- Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets
- Optimistic Outlook for Gilead Sciences Driven by Lenacapavir’s Market Potential
- Gilead price target raised to $95 from $92 at RBC Capital